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Introduction
Ebola virus (EBOV) (1, 2) is one of the deadliest pathogens 
in existence. Infection of a suitable host results in EBOV dis-
ease (EVD), which is characterized by the onset of a broad 
array of flu-like symptoms including fever, myalgia, and 
a general malaise. Disease progression leads to gastro- 
intestinal manifestations, multiple-organ failure, and eventual 
death in up to 90% of cases (3, 4). On March 22, 2014, WHO 
was notified by the MoH of Guinea that an outbreak of EVD 
was rapidly unfolding in the south-eastern region of the coun-
try, near the borders of Sierra Leone and Liberia (5). Genomic 
characterization of the virus identified it as a novel EBOV variant 
(strain Makona), with notable sequence heterogeneity compared 
with the 1995 Kikwit reference strain (5–7). Subsequently, Libe-
ria reported its first confirmed case (8), and by the end of May 
2014, Sierra Leone was also adding its name to the list of affected 
countries (9). Over a year has passed since the beginning of the 
largest documented Ebola outbreak, and to date (as of August 
12, 2015) there have been 27,948 cases (reported and confirmed) 
and 11,284 deaths. Disconcertingly, Sierra Leone has accounted 
for almost 50% of the case burden.
This study investigated the temporal changes in viral loads 
among laboratory-confirmed cases that were presented at the 
Kailahun Ebola Management Centre during a 5-month period 
of the outbreak and highlighted key factors that may have influ-
enced the progression of the epidemic.
BACKGROUND. Ebola virus (EBOV) causes periodic outbreaks of life-threatening EBOV disease in Africa. Historically, these 
outbreaks have been relatively small and geographically contained; however, the magnitude of the EBOV outbreak that began 
in 2014 in West Africa has been unprecedented. The aim of this study was to describe the viral kinetics of EBOV during this 
outbreak and identify factors that contribute to outbreak progression.
METHODS. From July to December 2014, one laboratory in Sierra Leone processed over 2,700 patient samples for EBOV 
detection by quantitative PCR (qPCR). Viremia was measured following patient admission. Age, sex, and approximate time of 
symptom onset were also recorded for each patient. The data was analyzed using various mathematical models to find trends 
of potential interest.
RESULTS. The analysis revealed a significant difference (P = 2.7 × 10–77) between the initial viremia of survivors (4.02 log10 
genome equivalents [GEQ]/ml) and nonsurvivors (6.18 log10 GEQ/ml). At the population level, patient viral loads were higher 
on average in July than in November, even when accounting for outcome and time since onset of symptoms. This decrease 
in viral loads temporally correlated with an increase in circulating EBOV-specific IgG antibodies among individuals who were 
suspected of being infected but shown to be negative for the virus by PCR.
CONCLUSIONS. Our results indicate that initial viremia is associated with outcome of the individual and outbreak duration; 
therefore, care must be taken in planning clinical trials and interventions. Additional research in virus adaptation and the 
impacts of host factors on EBOV transmission and pathogenesis is needed.
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the end of the data set in November when 
compared with July (slope = –0.01051 [95% 
CI, –0.01336 to –0.007661] log10 GEQ/ml 
per day). The mobile laboratory operated by 
the PHAC was not active between August 
25 and September 9, 2014, (epidemiological 
weeks 35–37), since the personnel was evac-
uated for safety reasons, explaining the gap 
in coverage for this time period (Figure 1A). 
However, the same equipment, reagents, 
and protocols were used before and after 
the evacuation. Many of the laboratory staff 
deployed from September to November 
had also been deployed in July or August. Staff members reported 
similar performance for internal controls before and after the gap.
A decrease of the mean initial viremia was observed when sam-
ples collected at the beginning of this study (first 2 weeks of July, 
when the EMC was initially opened) were compared with those 
taken immediately prior to the closing of the facility (final 2 weeks of 
November). The mean initial viremia for July was 6.168 log10 GEQ/
ml of blood (95% CI, 5.673–6.662), but had dropped to 5.110 log10 
GEQ/ml of blood (95% CI, 4.681–5.538) by November (Figure 1B). 
An unpaired, 2-tailed t test revealed this difference to be significant 
(t[108] = 3.184, P = 0.0019). To understand potential factors that may 
have played a role in the observed decrease in viral loads, we first 
compared the difference in days between the reported date of dis-
ease onset and the date of initial sampling. The analysis revealed that 
patients in July arrived to the EMC, on average, 6.7 (95% CI, 5.5–8.0) 
days after the reported onset of symptoms. This average was 7.2 (95% 
CI, 5.9–8.6) days for November (Figure 1C). An unpaired, 2-tailed t 
test indicated this difference to be nonsignificant (t[108] = 0.5220, 
P = 0.6028). Linear regression analysis revealed that, from July 1 to 
July 31, there was a nonsignificant 0.22 decrease in log10 GEQ/ml 
of blood [95% CI, –1.25–0.81]. Similarly, a nonsignificant 0.31 log 
increase in viral loads (95% CI, –0.48–1.10) was observed between 
July 1 and August 31. However, marked decreases were observed 
when the analysis spanned from July 1 to September 30 (–2.37 
log-units, 95% CI, –2.90 to –1.84), October 31 (–2.08 log-units; 95% 
CI, –2.56 to –1.61), and November 30 (–1.60 log-units; 95% CI, –2.04 
to –1.17) (Supplemental Table 2; supplemental material available 
online with this article; doi:10.1172/JCI83162DS1).
Viral load as a predictor of outcome. We next investigated whether 
age and viral loads at admission had an impact on patient outcome 
that changed during the outbreak. To this end, we categorized the 
Results
Characteristics of the study population. Approximately 1,200 peo-
ple were tested for EBOV infection at the Kailahun Ebola Man-
agement Center (EMC), of which 632 had a complete data set and 
were included in the analysis. The data set consisted of: age, sex, 
date of symptom onset, dates of all available sampling, viral load, 
and patient outcome (deceased or survived). Individuals without 
a complete data set were excluded from the analysis. The median 
age of the study population was 25 years old (mean: 26.9 years old; 
range: 4 months–75 years old). The population was composed of 
319 males and 313 females. Our dataset included 379 survivors 
and 253 fatalities for an overall case fatality rate (CFR) of 40%. 
The median time between symptom onset and diagnostic sam-
pling was 7 days, with an interquartile range of 6 days. The charac-
teristics of the cohort studied are summarized in Table 1.
Bivariable analyses. We initially compared viremia across the 
different aspects of the population, such as age, sex, and sur-
vivorship. Nonsurvivors had a significantly higher viremia on 
admission (6.18 log10 genome equivalents [GEQ]/ml of blood, 
95% CI, 6.04–6.32) compared with survivors (4.02 log10 GEQ/ml 
of blood, 95% CI, 3.89–4.15) (P = 2.70 × 10–77) (Table 1). Age 
(P = 0.0104) and time between symptom onset and sampling 
(P = 5.63 × 10–15) were also significantly associated with viremia. 
There was no difference in initial viremia between the sexes.
Outbreak kinetics. We first sought to determine if the initial viral 
loads of patients upon admission to the EMC changed over the course 
of the outbreak, regardless of outcome. The viral loads of 632 patients 
who tested positive for EBOV immediately following presentation at 
the EMC were plotted over the course of the epidemic (Figure 1A) 
and fitted to a linear regression. Analysis of this data indicated that 
the viral loads of patients following arrival at the EMC were lower at 
Figure 1. Characterization of the viral load 
levels. When applicable, the arithmetic mean 
is shown, and the error bars represent the 95% 
CI. (A) Initial viral loads of the selected 632 
patients throughout the outbreak in Kailahun, 
Sierra Leone. Linear regression is shown in red. 
(n = 632). (B) Initial viral loads of patients for 
the first 2 weeks of July (n = 43) and the last 
2 weeks of November (n = 67). (C) Number of 
days between the reported date of symptom 
onset and the date of the initial sampling at the 
EMC on the same data set from B. Two-tailed, 
unpaired t tests. **0.001 < P < 0.01.
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to the fraction of true negatives out of the condition negatives (true 
negatives plus false positives), and the PPV represents the fraction of 
true positives out of the test positives (true positives plus false pos-
itives). The optimal viral load threshold that was predictive of non-
survival for the month of July was 5.860 log10 GEQ/ml of blood (sen-
sitivity: 0.694 [95% CI, 0.554–0.805]; specificity: 0.864 [95% CI, 
0.751–0.932]; PPV: 0.810 [95% CI, 0.690–0.930]) (Supplemental 
Table 3). For November, the threshold value was 4.672 log10 GEQ/ml 
of blood (sensitivity: 0.752 [95% CI, 0.670–0.818]; specificity: 0.910 
[95% CI, 0.814–0.961]; PPV: 0.942 [95% CI, 0.897–0.987]) (Sup-
plemental Table 3). This later threshold could appropriately identify 
75.2% of individuals who died and 91% of the individuals who sur-
vived. Out of the individuals predicted not to survive, 94.2% died.
Effect of age on mortality. Mortality rates were compared 
between age groups using the χ2 test (χ2[3] = 18.888, P = 0.00029), 
followed by the Marascuillo procedure for comparing multiple 
proportions. It was observed that there was a marked difference 
in mortality between the 5- to 14-year-olds and the >40-year-olds, 
as well as between the 15- to 40-year-olds and the >40-year-olds.
Individual patient viral kinetics and survival. Patients who pre-
sented to the EMC and initially tested positive for EBOV were kept 
under observation and sampled to monitor disease progression and 
convalescence according to uneven clinical management require-
ments. To assess if the viral load kinetics of individual patients 
correlated with survival, we plotted the viremia of survivors and 
nonsurvivors over the course of disease for each month (Figure 3, 
A–E). It should be noted that nonsurvivors often have very few time 
points due to sudden mortality, thereby limiting this analysis (10). 
Therefore, survivors who had ≥5 samples and nonsurvivors with ≥2 
samples were used in our analysis, for a total of 40 patients. The 
various viral profiles did not reveal meaningful trends that would 
allow for outcome prediction on an individual-patient basis. This 
result is consistent with data previously reported regarding the 
Sudan virus (SUDV) outbreak in Gulu, Uganda (10). During that 
outbreak, it was determined that, while viremia in survivors was 
often found to start high and decrease over time, viremia in non-
survivors varied considerably. Interestingly, the second measure-
same 632 patients by viral load and calculated the CFRs for each 
group (Supplemental Figure 2). Viremia was arbitrarily classified as 
low, intermediate, or high (<4.24, 4.24–6.94, and >6.94 GEQ/ml, 
respectively, corresponding to Ct values of >30, 20–30, and <20). 
Only samples from July (Figure 2A) and November (Figure 2B) were 
investigated in order to evaluate differences observed in patients 
between the beginning and the end of data collection.
The analysis revealed that the CFR for July was significantly 
higher (52.7%, Figure 2A), than for November (30.9%, Figure 
2B) (χ2[1] = 22.862, P = 1.7 × 10–6). However, the differences in 
CFR for each viral load cluster were not significantly different 
between July and November 2014 (high viral load: χ2[2] = 0.715, 
P = 0.699; medium viral load: χ2[2] = 4.518, P = 0.104; low viral load 
χ2[2] = 2.650, P = 0.266). This is known as Simpson’s paradox: the dif-
ference in the overall rates is a result of the fact that the low and inter-
mediate viral loads are overrepresented in November (Supplemental 
Figure 3). However, the CFRs by viral load clusters were significantly 
different from each other within each month (July: χ2[2] = 49.432, 
P = 1.8 × 10–11; November: χ2[2] = 115.67, P ≤ 2.2 × 10–16), indicating that 
patients with different levels of viremia died at differing rates. The 
Marascuillo procedure for comparing multiple proportions showed 
that all 3 levels of viremia had statistically different fatality rates for 
both July and November. The analysis revealed that viral loads above 
6.94 log10 GEQ/ml of blood on admission led to fatal outcomes in 
89.1% of cases (95% CI, 81.3–96.9). In contrast, viral loads lower 
than 4.24 log10 GEQ/ml of blood on admission were associated with 
death in 7.4% of cases (95% CI, 5.8–9) (Supplemental Figure 2). Sim-
ilarly, there was a difference in outcomes between patients with high 
and intermediate viremia, and between intermediate and low vire-
mia, with the higher viremia linked to a higher fatality rate.
To identify the optimal threshold of viremia, which would be 
predictive of nonsurvival for each month (Figure 2C), a receiver 
operating characteristic analysis (ROC analysis) was performed. 
Three important summary values of ROC analysis are the sensitiv-
ity, the specificity, and the positive predictive value (PPV). The sen-
sitivity represents the fraction of true positives out of the condition 
positives (true positives plus false negatives), the specificity refers 
Table 1. Descriptive and bivariable analysis of the patients
Subjects EBOV viremia on admission (Log10 GEQ/ml)
Feature # Mean [95% CI] Difference [95% CI] P valueA
Sex Male 319 4.87 [4.69, 5.06] Base 0.8332
Female 313 4.90 [4.73, 5.07] 0.03 [–0.23, 0.28]
Age (years) <5 28 4.55 [3.94, 5.16] Base 0.0104
5–14 99 4.72 [4.42, 5.02] 0.17 [–0.72, 1.02]
15–40 381 4.79 [4.63, 4.96] 0.24 [–0.57, 1.06]
>40 124 5.38 [5.10, 5.66] 0.83 [–0.04, 1.63]
Sampling <5 days 172 5.58 [5.35, 5.80] Base 5.63 × 10–15
≥5 days 460 4.63 [4.48, 4.78] –0.95 [–1.22, –0.67]
Outcome Survivors 379 4.02 [3.89, 4.15] Base 2.70 × 10–77
Nonsurvivors 253 6.18 [6.04, 6.32] 2.16 [1.96, 2.36]
Total 632 4.89 [4.76, 5.02] – –
ADetermined using a 2-tailed unpaired equal variance t test for sex and survival. For age and time since onset of symptoms (sampling), the significance was determined using a linear 
regression of log10 GEQ/ml vs. age in years or log10 GEQ/ml vs. time since onset of symptoms.
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Kailahun, Sierra Leone (Figure 1A and Supplemental Figure 1). Inter-
estingly, the CFRs for each month followed an overall downward 
trend. The monthly CFRs were 52.7%, 67.4%, 31.8%, 32.9%, and 
30.9%, respectively (Figure 5). A χ2 test for independence revealed 
an association between month and CFR (χ2 = 118.37, degrees of 
freedom = 9, P < 2.2 × 10–16). The significant χ2 was followed by the 
Marascuillo procedure to compare multiple proportions, which 
showed significant differences in CFR between July and the months 
of September, October, and November, as well as between August 
and the months of September, October, and November (Supplemen-
tal Figure 4). It was hypothesized that increasing immunity in the 
population could be one of the contributors to the lower viral loads 
by reaching a herd immunity threshold as the outbreak progressed. 
To evaluate this hypothesis, the seroprevalence of EBOV-specific 
IgG was analyzed. Ninety-four patients who presented at the EMC 
for diagnostic testing, but who were determined to be negative for 
EBOV by reverse transcription PCR (RT-PCR) between July and 
November 2014, were assessed for EBOV-specific IgG. Out of 
these 94 patients, 46 reported history of contact with a sick person 
or funeral exposure; 17 reported no exposure to an infected individ-
ual or attendance to a funeral; and, for the 31 other individuals, the 
information was not available. Forty-five of these 94 patients (47.9%) 
had detectable IgG antibodies against EBOV (Supplemental Table 5). 
ment of viremia of patients who experienced a fatal outcome was 
lower than the first measurement in 4 of the 10 cases versus for 21 
of 26 survivors — a significant difference (χ2[1] = 8.47, P = 0.0036)
Change in initial viral load over time. To further examine the rela-
tionship between the viral load and outbreak progression, as well as 
viral load and mortality, a linear model was developed (Figure 4A; 
see Annex I in the supplemental material). This model allowed to 
account for any effect that the time since onset of symptoms may 
have had on viremia. Two additional potential predictors (sex and 
age) were also included in the model and were found to be unrelated 
to viremia in this dataset, once other predictors were accounted for 
(see Annex I in the supplemental material). The effect of time since 
the beginning of the outbreak was found to be more accurately mod-
eled as a quadratic relationship, suggesting that the viral loads were 
actually increasing toward the end of the data-collection period 
(Figure 4B). However, there is still a negative linear component to 
the regression, which explains why the simple linear regression in 
Figure 1A had a nonzero negative slope. The difference in viral load 
for survivors was 1.6 log10 GEQ/ml of blood lower than nonsurvi-
vors. This difference increases by 0.073 log10 GEQ/ml of blood with 
every day after the onset of symptoms (Figure 4C).
Survival correlates with population immunity. Initial viral loads 
of patients were higher in July when compared with November in 
Figure 2. Correlation between viral load and outcome for the months of July and November. The CFR (%) and the case survival rate (CSR, %) are stacked, 
divided by viral clusters of low (<4.24), intermediate (4.24–6.94) and high (>6.24) viremia and subdivided by age groups (below 5, between 5 and 14, 
between 15 and 40, and above 40 years old). (A and B) Months of July (n = 93) (A) and November (n = 165) (B) are represented. Survivors are shown in blue 
and nonsurvivors are shown in red. (C) Sensitivity and 1 minus specificity (ROC curves) are shown at various threshold values of viral loads for each month 
of the outbreak in Kailahun. (July: green, n = 47; August: yellow, n = 81; September: red, n = 134; October: orange, n = 159; November: blue, n = 164)
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virus replication could explain this phenomenon. This is in line 
with a previous study (10), which showed, in the context of SUDV 
infections, that predicting an outcome based on an overall viral-
load profile was not accurate. However, this could also be explained 
by an insufficient data set, where many nonsurvivors had few data 
points available. Therefore, this analysis cannot rule out that indi-
vidual kinetics could be associated with clinical outcome.
Linear modeling of the initial viremia as a function of (i) the 
time between onset of symptoms and sampling, (ii) the time 
since the beginning of data collection, and (iii) the outcome of the 
patients allowed for the analysis of subtler trends in the viremia. 
From the start of the outbreak, there was a difference in viremia 
of about 1.6 log-units (95% CI, 1.3–1.9) between survivors and 
nonsurvivors, and this difference increased as the outbreak pro-
gressed. However, a quadratic component to the relation between 
viremia and the time since the beginning of data collection also 
emerged, which suggests that the viremia was not decreasing dur-
ing the months of October and November. This explains why the 
decrease in viremia between July 1 and October 31 (or November 
30) was lower than the decrease between July 1 and September 30. 
As expected, the difference in viremia was also increasing with 
the time since onset of symptoms. These results suggest that, for 
fatal cases, the time since onset of symptoms had a neutral to pos-
itive effect on viremia, whereas, for the survivors, the more time 
The analysis indicated that immunity in EBOV-negative patients 
was increasing, concurrent with decreasing viral loads in infected 
patients (Figure 5). In July, the EBOV seroprevalence rate was 14.3% 
(1 patient out of 7; 95% CI, 0%–40.2%), while in September, the rate 
increased to 55.9% (19 patients out of 34; 95% CI, 44.3%–67.4%). 
This trend continued through October (12 patients out of 25; 48.0%; 
95% CI, 28.4%–67.6%) and November, where 13 patients out of 
28 (46.4%; 95% CI, 27.9%–64.9%) were seropositive for EBOV-
IgG. Linear regression analysis established that the increase in the 
monthly immunity was significant (F1,2 = 20.29, P = 0.0459). Unfor-
tunately, samples from late August 2014 were unavailable for test-
ing, which prevented us from further detailing the crossover in CFR 
and EBOV seroprevalence.
Discussion
The current findings suggest that the viral load of a patient on 
arrival to the EMC is statistically predictive of outcome. Individ-
ual viral kinetics were only associated with outcome in regards to 
the second viral load determination in relation to the first one (e.g., 
nonsurvivors tend to show higher second measurements). Interest-
ingly, 1/3 of the patients who experienced a fatal outcome were not 
following this trend — a counterintuitive observation, since virus 
clearance should be associated with survival. Presence of one or 
many co-morbidities or irreparable tissue damage resulting from 
Figure 3. Viral kinetics of individual patients throughout the outbreak. The viremia of individual patients was graphically represented by number of 
days after onset of symptoms. (A–E)Patients were divided by months of the outbreak in Kailahun, Sierra Leone, in July (n = 10) (A), August (n = 8) (B), 
September (n = 8) (C), October (n = 4) (D), and November (n = 10) (E). Each symbol for a given panel represents a single patient. Survivors are shown 
in blue, and nonsurvivors are shown in red.
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there was between onset of symptoms and sampling, the lower the 
viremia. Overall, this model supports other analyses in concluding 
that there was indeed a decrease in initial viremia, even when we 
account for variation in time since onset of symptoms.
An intriguing finding is the correlation between the observed 
increase in EBOV-specific antibodies in the population and the 
decrease in initial viral loads of infected patients. Previous work 
conducted by the Lassa Diagnostic Laboratory at the Kenema 
General Hospital (KGH), Sierra Leone, between October 2006 
and October 2008 revealed that 19 of the 220 (8.6%) serum sam-
ples tested during that period had an antibody response against 
EBOV (11). This number seems to be in accordance with another 
study conducted in rural areas of Gabon, a country that had been 
affected by 5 outbreaks of EBOV at the time of this serological 
survey. The Gabonese study, conducted from 2005–2008, estab-
lished that 667 participants out of 4,349 (15.3%) were seropos-
itive for EBOV-specific IgG (12). The higher seroprevalence 
observed in this last study compared with the one in Sierra Leone, 
despite similar sampling times, could potentially be explained by 
the higher occurrence of outbreaks in Gabon, leading to a larger 
fraction of the population being exposed to EBOV. A second study 
conducted at the KGH, from June 2011 to March 2014, analyzed 
a subset of 242 serum samples (13). Of those samples, between 
16 (6.8%) and 53 (22%) were seropositive for IgG against EBOV, 
depending on the stringency of the cut-off applied to the assay. 
The findings presented here with an immunity of 14% for the 
month of July are in accordance with this later study, despite the 
few data points available in the present analysis in July. Overall, 
these serological surveys demonstrate that EBOV-specific IgG 
can be found in the population outside of an epidemic context, 
but also in regions where an EBOV outbreak has never been docu-
mented. It should be noted that genomic analysis had postulated 
that the currently circulating strain may have diverged and been 
introduced to West Africa in 2004 (7). Thus, it is tempting to 
speculate that occasional exposure to this virus, which would gen-
erate a low level of population immunity, may have occurred prior 
to the current outbreak. A study published in 2000 suggested that 
asymptomatic, replicative Ebola infection can occur in humans 
and that a fraction of those individuals can develop an antibody 
response (14). Similar to the serosurveys mentioned above, the 
one conducted in the current study could only use a small num-
ber of samples relative to the number of patients used for viremia 
assessment. In addition, as in previous studies, it is important to 
mention that the results were generated from patients reporting 
at a clinic with symptoms (in the present case at the EMC) and 
not from a random sample of the community. In this case, specif-
ically, the patients were sick but EBOV-negative by quantitative 
PCR (qPCR), which may have introduced a bias and not necessar-
ily represent the immune status of the general population. There-
fore, although interesting, interpretation from these observations 
should be taken with caution until data from an extended number 
of samples are available.
Overall, the present data suggest a significant decrease in the 
viral loads over time in patients in their initial screen for EBOV 
upon arrival to the EMC in Kailahun, Sierra Leone. Hypotheses to 
explain this decrease are numerous and not mutually exclusive. 
As the outbreak progressed and more cases arose, the awareness 
of the disease among the population could have increased, and in 
the event that one family member fell ill, every household member 
could seek early medical care or actively reduce their exposure by 
limiting their contacts with sick individuals. However, the fact that 
there is no statistically significant difference in time between onset 
of symptoms and initial diagnostic sampling suggests that faster 
reporting to the EMC is not supported by the current data.
Figure 4. Linear model of the viremia. Estimating the difference 
between survivors and nonsurvivors, as well as the effect of outbreak 
duration on initial viremia. (n = 632). (A) Regression coefficients for the 
Makona outbreak; point estimates and 95% CI. Upper panel: All coef-
ficients. Lower panel: Excludes from the graphical representation the 
outcome to show the smaller coefficients. (B) Effect of outbreak dura-
tion for survivors and nonsurvivors. (Showing best line and 95% CI). (C) 
Effect of time since onset of symptoms at sampling time for survivors 
and nonsurvivors (showing best line and 95% CI).
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It also remains possible that the decrease is due to a detection 
bias. As the outbreak progressed, a growing spectrum of cases were 
identified and tested, whereas early in the outbreak, it is possible 
that more of the severe cases (with expected higher viremia) were 
detected and tested. Anecdotally, however, many individuals are 
still refusing to acknowledge the disease and prefer not to report 
to an EMC. Even now, over a year after the outbreak was officially 
declared, many security incidents are still being reported, indicat-
ing that there is still a lack of trust in certain populations toward 
healthcare facilities and outbreak responders. Another possibility 
is the existence of patients with atypical infections, who do not 
show traditional symptoms of EVD, such as subclinical infections. 
The individuals would be far more mobile than patients with a 
more typical infection. As such, individuals with an atypical infec-
tion could spread the virus ahead of the wave of severe infections 
and increase the levels of immunity in the population. Once the 
level of immunity reaches a critical threshold, fatality rates and 
viremia would go down, as observed in the present study.
It is fair to assume that, as the outbreak progresses through 
time, it is also progressing in geographical distribution. As the 
outbreak moved away from the epicenter, where the EMC was 
located, it is possible that severely afflicted patients were unable to 
complete or even undertake the journey to the EMC, thereby filter-
ing out the patients with the highest viremia. However, given that 
highly viremic patients tend to be very contagious, a large flare-
up would have been expected, which did not occur. Future work 
will need to assess the impact of this parameter, among others, on 
outbreak progression. Finally, another hypothesis to consider is 
genetic variation of the virus. As described recently (15), isolates 
collected in Kailahun from July to November 2014 were shown 
to have become more phylogenetically and genetically diverse, 
resulting in the emergence of a multitude of novel lineages. Even 
though this diversification has not been linked to any phenotype of 
the virus (16), it could be the result of an adaptation of EBOV to its 
host, resulting in slower replication and a lower viremia.
Overall, the current study offers a detailed view on viral 
loads in relation to epidemiological data from a highly active 
site of EBOV transmission and spread. These data could inform 
the development of vaccine, therapeutics, and importantly, the 
design of optimal clinical trials by associating promising clinical 
modalities in a way to better benefit a subgroup of individuals 
with the highest predicted CFR.
Methods
Study population. From July to November 2014, the mobile laboratory 
operated by the PHAC was deployed to provide diagnostic testing sup-
port at an EMC in the Kailahun district of Sierra Leone, managed by 
MSF. During these 5 months, over 2,700 samples from about 1,200 
patients were analyzed. December was excluded from the analysis, 
as there were only 2 positive cases during this month. Patients were 
screened on arrival at the EMC and relocated to the relevant areas of 
the EMC. Patients who tested positive for EBOV were kept at the EMC 
to receive care until final outcome (death or convalescence), while the 
ones who were found negative were released. The mobile laboratory 
staff was evacuated for safety reasons on August 25, 2014; the labora-
tory was reopened on September 10, 2014.
Procedures. Samples were received by the onsite laboratory and 
inactivated using a previously published method (17) inside a flexible 
film, negative pressure isolator using Rapid Containment Kit (Germ-
free Laboratories) followed by RNA extraction and purification. qPCR 
assays targeting the Ebola polymerase (L) and nucleoprotein (NP) 
genes were used to detect the presence of EBOV using Lightcycler 
480 RNA Master Hydrolysis reagents (Roche Diagnostics) according 
to manufacturer’s instructions. Primers and probes were as follows: 
ZEBOV LF (5′-CAGCCAGCAATTTCTTCCAT), ZEBOV LR (5′-TTTC-
GGTTGCTGTTTCTGTG), ZEBOV LP1 (FAM-ATCATTGGC/ZEN/
RTACTGGAGGAGCAG-BHQ1), ZEBOV LP2 (FAMTCATTGGCG/
ZEN/TACTGGAGGAGCAGG-BHQ1), ZEBOV NPF (5′-TGCCGAC-
GACGAGACGT), ZEBOV NP2 (5′-CGTCCCTGTCCTGTTCTTCAT), 
and ZEBOV NPP (FAM-AGYCTTCCG/ZEN/CCCTTGGAGTCAGA). 
Probes were obtained from IDT Labs and contained an internal 
quencher (/ZEN/), as indicated.
Assays were performed on the Lightcycler Nano platform (Roche 
Diagnostics). Primary testing focused on EBOV diagnosis using cut-
off cycle threshold (CT) values for positive, equivocal, and negative 
of ≤37, 37.1–40, and >40, respectively. The assays detected EBOV at 
approximately 10 genome equivalents/reaction. Differential diagnos-
tics were also offered for Lassa virus (18) and Plasmodium species (19). 
As an internal control for extraction and amplification procedures, MS2 
phage was added to each sample as previously described (20) to ensure 
that the extraction, PCR setup, and run parameters did not change 
between operators or over time. The data shown was generated from 
EDTA blood samples collected at the MSF EMC. CT values were con-
verted to GEQ/ml based on the average of 10 replicates of an in-house 
laboratory standard curve (Supplemental Table 1).
Figure 5. Evolution of the CFRs and 
immunity in the population. Monthly 
CFRs (blue triangles) and percentage 
of the tested population with an 
immunity to EBOV (purple squares) 
are overlaid with the initial viremia of 
the selected 632 patients (gray circles). 
Linear regression of the viremia is 
shown in red (n = 632).
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χ2 test followed by the Marascuillo procedure, if the χ2 test was signifi-
cant. The data cleaning, preparation, and analysis were performed 
using Revolution R open (based on R version 3.1.2, with a CRAN snap-
shot from April 30, 2015; Revolution Analytics). A P value less than 
0.05 was considered significant.
Study approval. This work was conducted as part of the inter-
national public health response to help with the containment of the 
outbreak in Sierra Leone, and therefore, informed consent was not 
obtained from individual patients. Ethics approval was obtained from 
the Government of Sierra Leone Ethic Review Board in Freetown to 
use, analyze, and publish controlled, unidentified, anonymous data 
collected during diagnostic testing. This study met the standards set 
by the independent MSF Ethics Review Board for retrospective analy-
ses of routinely collected programmatic data (21).
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IgG ELISA were performed using the Crocodile ELISA miniWork-
station (5-inone) (Titertek-Berthold). Polystyrene microtitre plates 
(Costar, Corning Inc.) were coated with 50 ng/well/100 μl of sucrose 
purified inactivated EBOV in PBS overnight at 4°C. Sucrose purified 
inactivated Marburg virus (MARV) was used as a negative control anti-
gen (Ag). Plates were washed with PBS containing 0.1% Tween-20 
(washing buffer), then blocked with 200 μl PBS-5% skim milk for 15 min-
utes at 37°C, before sera diluted in blocking solution (33 μl) was added for 
1 hour at 37°C. After washing, 100 μl of detection antibody (Peroxidase- 
conjugated goat anti-human IgG) (diluted 1:2,000 in blocking solution) 
was added for 1 hour at 37°C. Subsequently, plates were washed, and 
100 μl of substrate (2,2’-azino-bis[3-ethylbenzothiazoline-6-sulphonic 
acid] [ABTS]; KPL) was added to each well for 20 minutes at 37°C, before 
reading on a microplate reader at 405 nm. A sample was positive when 
the absorbance minus background was higher than the mean plus 4 stan-
dard derivations of the serum pool of 20 normal people.
Statistics. The overall linear regression of viremia over time, t tests, 
and ANOVA were performed using GraphPad Prism version 6.05. For t 
tests, Gaussian distribution was assumed and 2-tailed, unpaired equal 
variance t tests were conducted at a confidence level of 95%. Ordinary 
1-way ANOVAs with Tukey’s multiple comparisons test (single pooled 
variance) were conducted at a confidence level of 95%.
In order to assess the difference in viremia over time and between 
survivors and nonsurvivors, we used a linear model to account for 
other variables that may have impacted the viral loads. The predic-
tors we explored were: (i) the time (in days) since July 1, 2014; (ii) the 
time (in days) between the initial sample and onset of symptoms (the 
onset of symptoms was estimated by the patients and physicians); (iii) 
the age of the patient; and (iv) the sex of the patient. The significance 
threshold for including the individual main effects in the model was 
0.25, and the significance threshold for keeping a predictor in the full 
model was 0.1. The linearity of the relationships was verified graph-
ically; the time since July 1, 2014, was the only nonlinear predictor. 
The differences in CFRs between multiple groups were tested by the 
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